Unresolved issues of management of patients with severe allergic rhinitis  and nasal polyposis. The possibilities of anti-IgE therapy

Emelyanov, Alexander; Ilina, N I; Карнеева, О. В.; Karpishchenko, S.A.; Kim, I. A.; Kurbacheva, O. M.; Ненашева, Н М; Обухова, О. В.; Свистушкин, В. М.; Уханова, О П

doi:10.18692/1810-4800-2020-3-88-99

Cited by 9 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…I N P R E S S DOI: https://doi.org/10.36691/RJA1533 территориальных регистров пациентов с отдельными заболеваниями, требующими применения дорогостоящих лекарственных препаратов» 2 . В Тарифном соглашении по обязательному медицинскому страхованию СО от 28.12.2019, приложение № 13 3 , была произведена разгруппировка клинико-статистических групп, что позволило децентрализовать таргетную терапию больным ТБА.…”

Section: A R T I C L Eunclassified

“…Режим доступа: https://docs.cntd.ru/document/429068863. Дата обращения: 15.01.2022 3. Приложение 13 к Тарифному соглашению по ОМС от 28.12.2019 «Перечень КСГ, коэффициенты относительной затратоёмкости и тарифы на случай лечения по клинико-статистическим группам в условиях дневного стационара с 01.01.2020.…”

unclassified

See 1 more Smart Citation

The effectiveness of anti-IgE therapy for allergic rhinitis in patients with severe atopic bronchial asthma and concomitant allergic rhinitis in real clinical practice

Beltyukov

Naumova

2022

Russian Journal of Allergy

View full text Add to dashboard Cite

BACKGROUND: Omalizumab, by binding IgE in atopic patients, can improve clinical and functional parameters and patients' quality of life. AIMS: to evaluate efficacy of anti-IgE-therapy in patients with allergic rhinitis treated with omalizumab for concomitant severe atopic asthma in real clinical practice. MATERIALS AND METHODS: An open, non-interventional, prospective and non-randomized study in a real clinical practice. The study was conducted in the Sverdlovsk region in October 2021 based on a regional registry of adult patients with severe asthma with chronic nasal inflammatory diseases and receiving targeted therapy. Dynamics of nasal symptoms was assessed using SNOT-22 questionnaire and visual analogue scale initially, after 4 and 12 months of omalizumab therapy. Peripheral blood eosinophils level was also assessed before and after 4 months of omalizumab therapy. RESULTS: The study included 26 patients. Assessment of nasal symptoms dynamics using the SNOT22 questionnaire at baseline and after 4 months on omalizumab therapy revealed decrease in the severity of symptoms (p 0.001): baseline - 46.8522.04 points (95% CI 37.94-55.75), after 4 months - 30.6514.81 points (95% CI 24.67-36.64). Also improvement in SNOT22 questionnaire score was revealed in 18 patients treated with omalizumab during 12 month: before therapy - 47.5 points (Q₁ -Q₃: 35.7-59.3), after 4 months - 30.4 points (Q₁- Q₃: 22.1-38.1), after 12 months - 24.9 points (Q₁ -Q₃: 16.9-32.9) (p = 0.001). Improvement in rhinitis symptoms control was observed according to the VAS scale: VAS before therapy - 8.0 points (Q₁-Q₃: 6.2-9.0), after 4 months - 5.0 points (Q₁- Q₃: 3.2-5, 8), after 12 months of treatment - 5.0 points (Q₁-Q₃: 4.0-6.8). The level of eosinophils (n=16) decreased from 510.9317.9 (95% CI 341.5680.3) cells /l to 327.4217.7 (95% CI 211.4443.5) cells /l after 4 months of anti-IgE-therapy (p0.041). CONCLUSIONS: Omalizumab in real clinical practice has demonstrated improvement of rhinitis symptoms control and quality of life in patients with allergic rhinitis with concomitant severe atopic asthma. It was accompanied by a statistically significant decrease in peripheral blood eosinophils level, that largely determines airway inflammation severity and clinical manifestations of allergic rhinitis and bronchial asthma.

show abstract

Section: A R T I C L Eunclassified

unclassified

The effectiveness of anti-IgE therapy for allergic rhinitis in patients with severe atopic bronchial asthma and concomitant allergic rhinitis in real clinical practice

Beltyukov

Naumova

2022

Russian Journal of Allergy

View full text Add to dashboard Cite

show abstract

Assessment of the phenotypic composition of lymphocytes, immunoglobulins and their relationships in patients with chronic rinosinusitis

Smirnova,

Sinyakov,

Markina

et al. 2023

Vestn. otorinolaringol.

View full text Add to dashboard Cite

Effect of post-COVID syndrome on the quality of life of patients with allergic rhinitis and eosinophilic phenotype of chronic polyposis rhinosinusitis

Korkmazov,

Lengina,

Korkmazov

et al. 2023

Medical Journal of the Russian Federation

View full text Add to dashboard Cite

BACKGROUND.An urgent issue of modern medicine is the study of the quality of life of people with post-COVID syndrome.Particular emphasis is placed on patients with various forms of allergic rhinitis associated with comorbid conditions such as polyposis rhinosinusitis.These diseases are still common and tend to increase.In this context, the study of the effect of conservative methods of treatment of allergic rhinitis and polyposis rhinosinus on the quality of life of patients will improve the effectiveness of the therapy. AIMS: To assess the impact of post-COVID syndrome on the quality of life of patients with various forms of allergic rhinitis and eosinophilic phenotype of chronic polyposis rhinosinusitis and to determine the effectiveness of conservative therapy. MATERIALS AND METHODS: In the period from May to December 2021, a study was conducted on the quality of life in the treatment of 62 patients against the background of post-covid syndrome, of which 32 patients suffered from polypous rhinosinusitis and 30 patients with allergic rhinitis.The disease of coronavirus infection was registered 2-3 months before the visit to the otorhinolaryngologist.The comparison groups included 65 people, including 33 patients with polypous rhinosinusitis and 32 with various forms of allergic rhinitis.The Russian version of the standard SF-36 questionnaire was used to collect anamnesis.A visual analogue scale was used to measure the intensity of rhinological symptoms.All patients were examined three times: before treatment, 1 and 3 months after the course of therapy. RESULTS: A comparative analysis of the quality of life indicators of patients with various forms of allergic rhinitis and polyposis rhinosinusitis showed a direct dependence on the condition of patients after a coronavirus infection. CONCLUSIONS: The use of the assessment of quality of life indicators at the stages of treatment of patients with various forms of allergic rhinitis and polypous rhinosinusitis against the background of post-covid syndrome makes it possible to determine the effectiveness of conservative therapy and timely adjust the treatment.

show abstract

Unresolved issues of management of patients with severe allergic rhinitis and nasal polyposis. The possibilities of anti-IgE therapy

Cited by 9 publications

References 40 publications

The effectiveness of anti-IgE therapy for allergic rhinitis in patients with severe atopic bronchial asthma and concomitant allergic rhinitis in real clinical practice

The effectiveness of anti-IgE therapy for allergic rhinitis in patients with severe atopic bronchial asthma and concomitant allergic rhinitis in real clinical practice

Assessment of the phenotypic composition of lymphocytes, immunoglobulins and their relationships in patients with chronic rinosinusitis

Effect of post-COVID syndrome on the quality of life of patients with allergic rhinitis and eosinophilic phenotype of chronic polyposis rhinosinusitis

Contact Info

Product

Resources

About